DNA Vaccines 2010, March 2 - 4, 2010, New Orleans, LA
DNA Vaccines 2010 will be held March 2 - 4, 2010, at Sheraton New Orleans Hotel, New Orleans, LA. This meeting will follow the same successful pattern as the prior meeting for leading researcher to gather and report on the latest cutting edge research currently being undertaken in the progressive field of DNA or [...]
A New Trivalent Seasonal Influenza Candidate Vaccine Shows 78 Percent Rate of Prevention Against Matching Influenza Strains
Baxter International Inc., in conjunction with DynPort Vaccine Company LLC (DVC), announced Phase III study data measuring the clinical efficacy for PREFLUCEL, a trivalent seasonal influenza candidate vaccine. PREFLUCEL is made using Baxter’s Vero cell culture platform and does not contain an adjuvant or preservatives.
The Phase III clinical study found a 78 percent [...]
Leukemia Vaccine Shows Promise
BioSante Pharmaceuticals, Inc. announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate). BioSante owns the commercial rights to all GVAX vaccines as a result [...]
Cell-based Viral Vaccines: FDA Issues Final Guidance
To boost development of cell-based viral vaccines FDA issued final guidance. Today’s guidance outlines the best practices using current and emerging science to safely expand the types of cells that may be used to produce vaccines.
According to a recent market study “Global Pandemic Influenza Preparedness Market Forecast 2010-2015“, cell-based development will be the core of [...]
